Rapt Therapeutics stock price target raised to $41 from $24 at Clear Street

Rapt Therapeutics (NASDAQ:RAPT) saw its price target raised by Clear Street to $41 from $24, maintaining a Buy rating, following FDA clearance for its RPT904 Phase 2b food allergy trial, which significantly de-risks the asset and increased its probability of success to 60%. This development, alongside a 170% stock surge over six months, positions RPT904 to potentially offer a competitive advantage over omalizumab through less frequent dosing. Leerink, Wells Fargo, and JPMorgan also upgraded or maintained positive ratings, with further catalysts expected from upcoming Phase 2 chronic spontaneous urticaria and asthma data from its Chinese partner.

Analysis

Rapt Therapeutics (RAPT) has received significant positive re-ratings from analysts following the FDA's clearance of its Investigational New Drug (IND) application for RPT904, allowing a Phase 2b trial in food allergies. This regulatory milestone is viewed as a major de-risking event, prompting Clear Street to increase the drug's probability of success to 60% from 40% and raise its price target to $41.00. The market has reacted strongly, with the stock surging 170% over the past six months to trade near its 52-week high. The bullish consensus is broad, with Leerink upgrading the stock to Outperform, Wells Fargo maintaining an Overweight rating with a $38 target, and JPMorgan upgrading to Neutral from Underweight. Fundamentally, the company also reported a smaller-than-expected Q2 net loss per share of ($0.65). The core investment thesis centers on RPT904's potential competitive advantage over omalizumab (XOLAIR), based on a less frequent dosing schedule of 8-12 weeks versus 2-4 weeks. Near-term catalysts include data from Rapt's Chinese partner, Jemicare, on head-to-head trials against omalizumab in chronic spontaneous urticaria and asthma, which will be critical for validation. However, investors should note the long-term timeline, as the Phase 2b food allergy trial is set to begin by year-end 2025 with topline data not expected until the first half of 2027.

Key Decisions for Investors

• Given the broad analyst consensus and significant de-risking of RPT904, investors could view the recent FDA clearance as a positive inflection point, with price targets from Clear Street ($41) and Wells Fargo ($38) suggesting further upside potential despite the recent 170% rally.
• It is critical to monitor upcoming data from the Jemicare-partnered Phase 2 trials in CSU and asthma, as positive results from these head-to-head studies against omalizumab would further validate RPT904's competitive profile and serve as the next major catalyst.
• Investors should weigh the significant stock appreciation against the long-term clinical development timeline, as pivotal data for the food allergy indication is not expected until H1 2027, introducing long-term execution risk.